Pharmaceutical companies are increasingly shifting research and development spending to socalled orphan drugs: medications for patients with rare diseases, which can be sold at exorbitant costs. The upside is that patients with rare conditions now have access to life-saving medications. But as THE WEEKLY found out, it could also bankrupt their employers. We tell the story of an American woman...
Show more
